FDA 483 - Xellia Pharmaceuticals USA LLC - February 07, 2022
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Xellia Pharmaceuticals USA LLC in Bedford, OH, a manufacturer of sterile drug products, revealed a significant lapse in quality control unit procedures. The firm failed to submit a field alert report within the required three-day timeframe following notification of an out-of-specification stability result for a distributed batch of Vancomycin Hydrochloride for Injection USP. This delay indicates a failure to adhere to established internal procedures for critical product quality issues.
ID · 2f5255cd-c4f9-46a6-aad5-f2c327bae925